506 related articles for article (PubMed ID: 19125127)
1. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.
Palomaki GE; McClain MR; Melillo S; Hampel HL; Thibodeau SN
Genet Med; 2009 Jan; 11(1):42-65. PubMed ID: 19125127
[No Abstract] [Full Text] [Related]
2. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):35-41. PubMed ID: 19125126
[TBL] [Abstract][Full Text] [Related]
3. Genetic counseling and cascade genetic testing in Lynch syndrome.
Hampel H
Fam Cancer; 2016 Jul; 15(3):423-7. PubMed ID: 26969309
[TBL] [Abstract][Full Text] [Related]
4. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome.
Steinke V; Engel C; Büttner R; Schackert HK; Schmiegel WH; Propping P
Dtsch Arztebl Int; 2013 Jan; 110(3):32-8. PubMed ID: 23413378
[TBL] [Abstract][Full Text] [Related]
5. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
Chen YE; Kao SS; Chung RH
PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
[TBL] [Abstract][Full Text] [Related]
7. Informed consent and immunohistochemistry screening for Lynch syndrome.
Williams JL; Williams MS
Genet Med; 2011 Sep; 13(9):848-9. PubMed ID: 21885923
[No Abstract] [Full Text] [Related]
8. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
[TBL] [Abstract][Full Text] [Related]
9. On the advent of MSI testing of all colorectal cancers and a substantial part of other Lynch syndrome-related neoplasms.
Dinjens WN; van Leerdam ME; Wagner A
Expert Rev Mol Diagn; 2010 May; 10(4):381-4. PubMed ID: 20465492
[No Abstract] [Full Text] [Related]
10. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
[TBL] [Abstract][Full Text] [Related]
11. Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.
Kravochuck SE; Church JM
ANZ J Surg; 2017 Dec; 87(12):1006-1010. PubMed ID: 26990828
[TBL] [Abstract][Full Text] [Related]
12. Lynch syndrome in the 21st century: clinical perspectives.
Tiwari AK; Roy HK; Lynch HT
QJM; 2016 Mar; 109(3):151-8. PubMed ID: 26224055
[TBL] [Abstract][Full Text] [Related]
13. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma.
Metcalfe MJ; Petros FG; Rao P; Mork ME; Xiao L; Broaddus RR; Matin SF
J Urol; 2018 Jan; 199(1):60-65. PubMed ID: 28797715
[TBL] [Abstract][Full Text] [Related]
14. Molecular tumor testing for Lynch syndrome in patients with colorectal cancer.
Matloff J; Lucas A; Polydorides AD; Itzkowitz SH
J Natl Compr Canc Netw; 2013 Nov; 11(11):1380-5. PubMed ID: 24225971
[TBL] [Abstract][Full Text] [Related]
15. Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer (HNPCC).
Nallamilli BRR; Hegde M
Curr Protoc Hum Genet; 2017 Jul; 94():10.12.1-10.12.23. PubMed ID: 28696559
[TBL] [Abstract][Full Text] [Related]
16. Review article: genetic testing and counselling for hereditary colorectal cancer.
Trimbath JD; Giardiello FM
Aliment Pharmacol Ther; 2002 Nov; 16(11):1843-57. PubMed ID: 12390093
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
Piñol V; Castells A; Andreu M; Castellví-Bel S; Alenda C; Llor X; Xicola RM; Rodríguez-Moranta F; Payá A; Jover R; Bessa X;
JAMA; 2005 Apr; 293(16):1986-94. PubMed ID: 15855432
[TBL] [Abstract][Full Text] [Related]
18. Correspondence (reply): In reply.
Steinke V; Propping P; Engel C; Büttner R; Schackert K; Schmiegel WH
Dtsch Arztebl Int; 2013 May; 110(20):364. PubMed ID: 23825490
[No Abstract] [Full Text] [Related]
19. Uterine cancer could be harbinger of other cancers. An inherited mutation--Lynch syndrome--may lead to higher risk.
Duke Med Health News; 2006 Nov; 12(11):9-10. PubMed ID: 17228398
[No Abstract] [Full Text] [Related]
20. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer.
Xiao B; Luo J; Xie E; Kong L; Tang J; Liu D; Mao L; Sui Q; Li W; Hong Z; Pan Z; Jiang W; Ding PR
Eur J Hum Genet; 2020 Nov; 28(11):1555-1562. PubMed ID: 32661327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
